Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers
Prabhani U. Atukorale, Taylor J. Moon, Alexandr R. Bokatch, Christina F. Lusi, Jackson T. Routhier, Victoria J. Deng, Efstathios Karathanasis
Abstract
Neoadjuvant combination immunotherapy based on a potent immunostimulatory nanoparticle resulted in significant efficacy, curative responses, and protective immunological memory.
Topics & Concepts
ImmunotherapyCancer researchMedicineAgonistCD8MelanomaCancerMetastasisCancer immunotherapyT cellBreast cancerImmune systemImmunologyInternal medicineReceptorImmunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkersinterferon and immune responses